A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples